Table 2.
Association of ERCC1 Expression with Clinical Characteristics
Positive No. | Negative No. | P value | |
---|---|---|---|
Age (years) | 0.750 | ||
Median (range) | 58 (24–84) | 58 (30–87) | |
Race | |||
White | 98 | 274 | 0.928 |
Black | 6 | 14 | |
Other* | 4 | 12 | |
Performance Status | |||
0 | 49 | 134 | 0.970 |
1 | 52 | 148 | |
2 | 7 | 18 | |
Stage/Debulking | 0.936 | ||
Stage III – microscopic | 31 | 90 | |
Stage III – optimal | 53 | 139 | |
Stage III – suboptimal | 13 | 42 | |
Stage IV | 11 | 29 | |
Histology | |||
Serous | 80 | 241 | 0.277 |
Endometrioid | 6 | 20 | |
Clear cell | 7 | 10 | |
Mucinous | 0 | 2 | |
Others† | 15 | 27 | |
Tumor Grade | |||
1 | 11 | 25 | 0.671 |
2 | 43 | 111 | |
3 | 54 | 164 |
Other includes Hispanic, Asian or Pacific Islander.
Other histologic subtypes included: mixed epithelial, undifferentiated, transitional cell and adenocarcinoma, not otherwise specified